InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,118.13
(
0.53%
)
Post# of 251796
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4082
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: ronpopeil post# 232779

Friday, 05/29/2020 11:42:52 AM

Friday, May 29, 2020 11:42:52 AM

Post# of 251796

TRIL update

https://ir.trilliumtherapeutics.com/press-releases/press-release-details/2020/Trillium-Therapeutics-Provides-Update-on-the-Phase-I--Dose-Escalation-Study-of-Its-CD47-Blocker-TTI-622--at-the-ASCO20-Virtual-Scientific-Program/default.aspx



Ron, thanks. Here is the link to the poster. The data is a monotherapy dose escalation of TRIL's second anti-CDC47 blocker drug TTI-622. The trial is listed as also being combination therapy but no mention here. Looks promising.

https://s22.q4cdn.com/183592819/files/ASCO-2020-TTI-622-01-Poster-FINAL.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up